Loading...

Hofseth BioCare

DB:HBQ
Snowflake Description

Excellent balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
HBQ
DB
NOK772M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Hofseth BioCare ASA, a biotech company, offers value added biomarine ingredients and finished products for human consumption and pet in Norway. The last earnings update was 34 days ago. More info.


Add to Portfolio Compare Print
HBQ Share Price and Events
7 Day Returns
1.1%
DB:HBQ
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-
DB:HBQ
-9.2%
DE Biotechs
-6.7%
DE Market
HBQ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Hofseth BioCare (HBQ) 1.1% 5.2% - - - -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • No trading data on HBQ.
  • No trading data on HBQ.
Price Volatility
HBQ
Industry
5yr Volatility vs Market

HBQ Value

 Is Hofseth BioCare undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Hofseth BioCare. This is due to cash flow or dividend data being unavailable. The share price is €0.265.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Hofseth BioCare's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Hofseth BioCare's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:HBQ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in NOK NOK-0.33
OB:HBC Share Price ** OB (2019-04-18) in NOK NOK2.62
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Hofseth BioCare.

DB:HBQ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OB:HBC Share Price ÷ EPS (both in NOK)

= 2.62 ÷ -0.33

-7.98x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Hofseth BioCare is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Hofseth BioCare is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Hofseth BioCare's expected growth come at a high price?
Raw Data
DB:HBQ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.98x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Hofseth BioCare, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Hofseth BioCare's assets?
Raw Data
DB:HBQ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in NOK NOK0.29
OB:HBC Share Price * OB (2019-04-18) in NOK NOK2.62
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:HBQ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OB:HBC Share Price ÷ Book Value per Share (both in NOK)

= 2.62 ÷ 0.29

8.91x

* Primary Listing of Hofseth BioCare.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Hofseth BioCare is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Hofseth BioCare's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Hofseth BioCare has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

HBQ Future Performance

 How is Hofseth BioCare expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hofseth BioCare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.4%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Hofseth BioCare expected to grow at an attractive rate?
  • Unable to compare Hofseth BioCare's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Hofseth BioCare's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Hofseth BioCare's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:HBQ Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:HBQ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in NOK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:HBQ Past Financials Data
Date (Data in NOK Millions) Revenue Cash Flow Net Income *
2018-12-31 61 -29 -85
2018-09-30 73 -75 -74
2018-06-30 84 -3 -66
2018-03-31 75 -20 -66
2017-12-31 66 -25 -16
2017-09-30 43 -18 -28
2017-06-30 19 -43 -60
2017-03-31 21 -70 -92
2016-12-31 20 -67 -147
2016-09-30 21 -8 -165
2016-06-30 34 -2 -137
2016-03-31 32 1 -110

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Hofseth BioCare is high growth as no earnings estimate data is available.
  • Unable to determine if Hofseth BioCare is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:HBQ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Hofseth BioCare Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:HBQ Past Financials Data
Date (Data in NOK Millions) EPS *
2018-12-31 -0.33
2018-09-30 -0.31
2018-06-30 -0.28
2018-03-31 -0.28
2017-12-31 -0.07
2017-09-30 -0.12
2017-06-30 -0.29
2017-03-31 -0.52
2016-12-31 -1.01
2016-09-30 -1.39
2016-06-30 -1.22
2016-03-31 -1.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Hofseth BioCare will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Hofseth BioCare's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Hofseth BioCare's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Hofseth BioCare's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Hofseth BioCare's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Hofseth BioCare has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

HBQ Past Performance

  How has Hofseth BioCare performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Hofseth BioCare's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Hofseth BioCare does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Hofseth BioCare's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Hofseth BioCare's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Hofseth BioCare's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Hofseth BioCare Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:HBQ Past Revenue, Cash Flow and Net Income Data
Date (Data in NOK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 60.74 -84.77 42.81
2018-09-30 72.67 -74.21 36.38
2018-06-30 83.68 -65.91 35.70
2018-03-31 74.60 -66.39 35.66
2017-12-31 66.23 -16.48 33.94
2017-09-30 42.93 -28.30 27.09
2017-06-30 18.58 -60.24 23.65
2017-03-31 21.25 -91.52 21.35
2016-12-31 20.20 -147.45 20.91
2016-09-30 20.84 -165.03 25.80
2016-06-30 33.90 -137.37 27.62
2016-03-31 32.11 -109.50 28.45
2015-12-31 32.14 -100.19 26.71
2015-09-30 37.51 -84.30 21.68
2015-06-30 22.58 -81.82 21.76
2015-03-31 23.58 -72.19 22.11
2014-12-31 19.77 -66.92 22.09
2014-09-30 38.72 -40.48 27.42
2014-06-30 62.48 -35.19 29.68
2014-03-31 63.02 -39.46 30.49
2013-12-31 62.94 -52.14 31.35
2013-09-30 41.28 -97.55 30.63
2013-06-30 27.30 -96.12 26.24
2013-03-31 25.94 -88.54 25.63
2012-12-31 26.02 -73.86 23.54
2012-09-30 19.86 -34.86 16.58
2012-06-30 8.60 -32.08 14.54

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Hofseth BioCare has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Hofseth BioCare has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Hofseth BioCare improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Hofseth BioCare's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Hofseth BioCare has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

HBQ Health

 How is Hofseth BioCare's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Hofseth BioCare's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Hofseth BioCare is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Hofseth BioCare's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Hofseth BioCare's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Hofseth BioCare Company Filings, last reported 3 months ago.

DB:HBQ Past Debt and Equity Data
Date (Data in NOK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 86.04 58.30 48.64
2018-09-30 109.67 56.17 58.05
2018-06-30 -3.92 74.53 10.51
2018-03-31 14.92 66.03 23.79
2017-12-31 37.08 81.43 42.07
2017-09-30 49.98 40.43 29.78
2017-06-30 62.01 33.10 18.16
2017-03-31 81.32 64.36 64.40
2016-12-31 53.56 74.45 16.17
2016-09-30 77.07 84.78 39.79
2016-06-30 -23.55 122.16 0.95
2016-03-31 4.38 99.05 2.87
2015-12-31 32.55 98.62 28.87
2015-09-30 72.96 113.02 2.10
2015-06-30 89.27 122.98 30.61
2015-03-31 60.07 106.33 0.49
2014-12-31 78.95 100.41 2.54
2014-09-30 105.93 86.62 0.76
2014-06-30 118.84 84.45 3.93
2014-03-31 48.39 98.58 1.03
2013-12-31 62.00 96.65 3.97
2013-09-30 70.69 88.52 3.47
2013-06-30 78.33 78.91 4.24
2013-03-31 75.95 91.56 1.49
2012-12-31 47.72 68.53 2.24
2012-09-30 92.34 62.05 5.62
2012-06-30 99.62 33.16 1.60
  • Hofseth BioCare's level of debt (67.8%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (156.3% vs 67.8% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Hofseth BioCare has sufficient cash runway for 1.3 years based on current free cash flow.
  • Hofseth BioCare has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 15.2% each year.
X
Financial health checks
We assess Hofseth BioCare's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Hofseth BioCare has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

HBQ Dividends

 What is Hofseth BioCare's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Hofseth BioCare dividends.
If you bought €2,000 of Hofseth BioCare shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Hofseth BioCare's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Hofseth BioCare's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:HBQ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Hofseth BioCare has not reported any payouts.
  • Unable to verify if Hofseth BioCare's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Hofseth BioCare's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Hofseth BioCare has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Hofseth BioCare's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Hofseth BioCare afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Hofseth BioCare has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

HBQ Management

 What is the CEO of Hofseth BioCare's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Roger Hofseth
COMPENSATION NOK483,708
AGE 44
TENURE AS CEO 1.7 years
CEO Bio

Mr. Roger Hofseth has been the Chief Executive Officer of Hofseth BioCare ASA since August 14, 2017. He is Director at Aqua Bio Technology ASA since January 9, 2019. Mr. Hofseth serves as the Chief Executive Officer of Hofseth International. Mr. Hofseth has 20 years of experience in the fishery and food industry. This experience includes the founding of several companies and holding the position as member of the board and/or management position in several companies within the fishery, fish farming and ecological food industry. He served as the Chairman of Hofseth BioCare ASA since January 4, 2016 and served as its Director since 2009 to September 2017. Mr. Hofseth serves as the Chairman for Norsk Fisketerminal, Roger Hofseth and Tyco Invest. He serves as a member of board of Directors at Syvde Eiendom AS, Forex Holding, Hofseth, Hofseth International and Seafood Farmers of Norway. Mr. Hofseth served as Director of Vanylven Vekst HF. He served as a Member of the Board of Directors of Hofseth Bio Care from June 2010 to October 2011.

CEO Compensation
  • Roger's compensation has been consistent with company performance over the past year.
  • Roger's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Hofseth BioCare management team in years:

3.3
Average Tenure
41
Average Age
  • The tenure for the Hofseth BioCare management team is about average.
Management Team

Jon Ødegård

TITLE
Chief Financial Officer
COMPENSATION
NOK2M
TENURE
2.7 yrs

Bomi Framroze

TITLE
Chief Scientific Officer
COMPENSATION
NOK4M
AGE
57
TENURE
9.3 yrs

Henriette Heggdal

TITLE
Lab Manager & Director
COMPENSATION
NOK902K
AGE
37
TENURE
4.3 yrs

Roger Hofseth

TITLE
Chief Executive Officer
COMPENSATION
NOK484K
AGE
44
TENURE
1.7 yrs

Karl Slotsvik

TITLE
Chief Operating Officer
TENURE
2 yrs

Kai Thuen

TITLE
Marketing Manager
COMPENSATION
NOK902K
AGE
41
TENURE
4.7 yrs

Matt Mixter

TITLE
Managing Partner of Hofseth North America
COMPENSATION
NOK1M
AGE
34
TENURE
3.3 yrs

Olav Flaten

TITLE
Executive
Board of Directors Tenure

Average tenure and age of the Hofseth BioCare board of directors in years:

4
Average Tenure
45
Average Age
  • The tenure for the Hofseth BioCare board of directors is about average.
Board of Directors

Ola Holen

TITLE
Chairman
COMPENSATION
NOK138K
AGE
57
TENURE
1.6 yrs

Henriette Heggdal

TITLE
Lab Manager & Director
COMPENSATION
NOK902K
AGE
37
TENURE
5.3 yrs

Torill Eliassen

TITLE
Director
COMPENSATION
NOK116K
AGE
43
TENURE
3.8 yrs

Christoph Baldegger

TITLE
Director
COMPENSATION
NOK96K
AGE
47
TENURE
4.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
24. Jan 19 Buy Hofseth International AS Company 24. Jan 19 24. Jan 19 185,714 €0.26 €48,708
X
Management checks
We assess Hofseth BioCare's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Hofseth BioCare has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

HBQ News

Simply Wall St News

HBQ Company Info

Description

Hofseth BioCare ASA, a biotech company, offers value added biomarine ingredients and finished products for human consumption and pet in Norway. Its products include OmeGo salmon oil; ProGo, a salmon protein hydrolysate powder used as a fast absorbing protein supplement; and CalGo, a marine calcium powder produced from salmon bones that enhances bone density and bone deposition in older individuals. The company was founded in 2000 and is headquartered in Ålesund, Norway.

Details
Name: Hofseth BioCare ASA
HBQ
Exchange: DB
Founded: 2000
NOK80,706,582
294,836,829
Website: http://www.hofsethbiocare.no
Address: Hofseth BioCare ASA
Havnegata 11,
Ålesund,
Møre og Romsdal, 6005,
Norway
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OB HBC Common Shares Oslo Bors NO NOK 02. Dec 2011
OTCPK HOFB.F Common Shares Pink Sheets LLC US USD 02. Dec 2011
DB HBQ Common Shares Deutsche Boerse AG DE EUR 02. Dec 2011
LSE 0Q6H Common Shares London Stock Exchange GB NOK 02. Dec 2011
BATS-CHIXE HBCO Common Shares BATS 'Chi-X Europe' GB NOK 02. Dec 2011
Number of employees
Current staff
Staff numbers
44
Hofseth BioCare employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:56
End of day share price update: 2019/04/18 00:00
Last earnings filing: 2019/03/15
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.